Knight Therapeutics (TSE:GUD) Sets New 52-Week High – Here’s What Happened

Knight Therapeutics Inc. (TSE:GUD) hit a new 52-week high on Wednesday . The company traded as high as C$8.87 and last traded at C$8.62, with a volume of 146776 shares trading hands. The stock had previously closed at C$8.66.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group set a C$9.50 price objective on Knight Therapeutics and gave the company a “buy” rating in a research note on Friday, May 8th. One analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of C$9.50.

Knight Therapeutics Price Performance

The company has a debt-to-equity ratio of 8.86, a current ratio of 2.32 and a quick ratio of 1.79. The stock has a 50 day moving average price of C$7.17 and a two-hundred day moving average price of C$6.42. The firm has a market capitalization of C$846.93 million, a price-to-earnings ratio of 143.67, a PEG ratio of -1,013.50 and a beta of -0.21.

Knight Therapeutics (TSE:GUD) last issued its quarterly earnings data on Thursday, May 7th. The company reported C$0.13 earnings per share for the quarter. Knight Therapeutics had a return on equity of 0.73% and a net margin of 1.10%.The business had revenue of C$147.59 million during the quarter. As a group, analysts expect that Knight Therapeutics Inc. will post 0.1009486 EPS for the current year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.